Studies of GLP-1 discontinuation show that without continued therapy or behavioral structure, most patients regain two-thirds of lost weight within a year
Antipsychotics: Collaboration with psychiatry is essential
However, in the most recent analysis, researchers examined data from four major clinical trials and reported finding no significant correlation
CJC-1295 No DAC serves as a short-acting GHRH analog, while Ipamorelin acts as a selective ghrelin mimetic
Our promise Hormones, weight loss, peptides, and aesthetics in one NP-led home no dismissive "it's just aging" answers
GLP-1 medications, on the other hand, may be better suited for: Patients who are medication sensitive and prefer a single-pathway approach Those who want a slower, steadier progression with gradual appetite changes Individuals primarily struggling with appetite control rather than metabolic dysfunction For these patients, GLP-1 therapy may provide sufficient appetite regulation without the need for more aggressive metabolic intervention